25447 Baricitinib treatment results in clinically meaningful itch reduction and enhanced quality of life in patients with moderate-to-severe atopic dermatitis: Results from BREEZE-AD5

Category Primary study
JournalJournal of the American Academy of Dermatology
Year 2021
This article has no abstract
Epistemonikos ID: f64d3ca8cfd50676d17c219dc8ef4009e755c74c
First added on: Feb 13, 2025